63.9 F
New York
May 24, 2022
QuickBooks Payroll - Free 30-Day Trial
News

Self-administered inhaled painkiller shows superiority in prehospital setting


A new study has revealed an inhaled analgesic recently introduced to the UK is the most effective form of severe pain relief in the prehospital setting following traumatic injury, when it comes to speed of pain reduction.

Treatment during the first hour after trauma is essential to improve patient survival and good analgesia can lead to easier injury management and the potential to avoid chronic pain development. Despite this, less than a third of people in UK ambulances are given appropriate pain relief.

The year-long MAPIT study, led by Professor Aloysius Niroshan Siriwardena of the University of Lincoln, UK, and completed by East Midlands Ambulance Service, showed that the analgesic Penthrox®▼ (methoxyflurane), acts a lot more than three times quicker than the most often used – and also inhaled – analgesic, Entonox® (gas and air), more than three times quicker than intravenous paracetamol, and two times as quick as intravenous morphine to lessen severe pain.

Methoxyflurane, which has been dubbed the ‘green whistle’ was already proven to be a convenient and effective choice for pain relief, leading to a significant decrease in time spent in the hospital emergency department. Even though it is used regularly in UK emergency departments, it is not widely used in ambulances.

The data in the MAPIT study, was today (Tuesday 23rd March) shared at the 999 EMS Research Forum Annual Conference, providing the first comprehensive UK comparison of analgesic options utilized by paramedics and emergency medical technicians.

The evidence means prehospital emergency staff can now feel confident when choosing methoxyflurane as a first-line treatment option for moderate-to-severe trauma pain.

Rapid and efficient pre-hospital analgesia has the potential to improve the patient journey end-to-end. Using the NHS continuing to face an exceptional crisis following the outbreak of COVID-19 and unprecedented amounts of pressure to free up resources across all treatment settings, the research results are welcome news.

Chief Investigator, Professor Aloysius Niroshan Siriwardena, commented: “There are lots of barriers to adequate pain relief. This study is the first to check methoxyflurane with all other commonly used analgesics within the prehospital setting and the superior results increase the weight of positive findings from other UK and European hospital studies.

“From an academic perspective, it's an important addition to the evidence, and we look forward to seeing how greater uptake impacts patients in other ambulance trusts.”

Dr Leon Roberts, Medical Director for East Midlands Ambulance Service NHS Trust, which completed the study, commented: “Rapid and efficient pain relief is undeniably important in the prehospital setting and this study implies that emergency care staff have access to a well-tolerated treatment, which is simple to administer.

“EMAS is proud to become a leading organisation in prehospital research collaborating with key partners like the University of Lincoln, who has analysed and evaluated this data.”

Related posts

Nottinghamshire visitor economy to be celebrated at much talked about event

admin

Pick Everard selected for being element of new NHS framework

admin

Students urged to take into account apprenticeships as Government looks set to miss 2020 target

admin

Leave a Comment